Radiomics and molecular analysis:Bridging the gap for predicting hepatocellular carcinoma prognosis  

作　　者：Chun-Han Cheng Wen-Rui Hao Tzu-Hurng Cheng 

机构地区：[1]Department of Medical Education,Linkou Chang Gung Memorial Hospital,Taoyuan 33305,Taiwan,China [2]Division of Cardiology,Department of Internal Medicine,Shuang Ho Hospital,Ministry of Health and Welfare,Taipei Medical University,New Taipei 23561,Taiwan,China [3]Division of Cardiology,Department of Internal Medicine,School of Medicine,College of Medicine,Taipei Medical University,Taipei 11002,Taiwan,China [4]Department of Biochemistry,School of Medicine,College of Medicine,China Medical University,Taichung 404333,Taiwan,China

出　　处：《World Journal of Clinical Cases》2025年第4期56-60,共5页世界临床病例杂志（英文）

摘　　要：This editorial examines a recent study that used radiomics based on computed tomography(CT)to predict the expression of the fibroblast-related gene enhancer of zeste homolog 2(EZH2)and its correlation with the survival of patients with hepatocellular carcinoma(HCC).By integrating radiomics with molecular analysis,the study presented a strategy for accurately predicting the expression of EZH2 from CT scans.The findings demonstrated a strong link between the radiomics model,EZH2 expression,and patient prognosis.This noninvasive approach provides valuable insights into the therapeutic management of HCC.

关 键 词：Hepatocellular carcinoma Computed tomography Radiomics Enhancer of zeste homologue 2 expression Non-invasive imaging 

分 类 号：R735.7[医药卫生—肿瘤]